Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance

Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation‘s (NYSE:BSX) momentum—and hint at where its next product wins may come.

Boston Scientific on Wednesday reported second-quarter 2025 revenues of $5.06 billion, beating the consensus estimate of $4.89 billion.

“This was another excellent quarter, marked by exceptional top-line performance, that delivered margin expansion and prioritized investment for future growth,” said Mike Mahoney, chairman and CEO, Boston Scientific.

The medical technology giant reported adjusted earnings of 75 cents, beating the consensus of 72 cents and the management guidance of 71-73 cents.

Sales increased 22.8% on a reported basis, compared to the company's guidance range of 17.5%-19.5%, and 21.6% on an operational basis, 17.4% on an organic basis, compared to the company's guidance range of 13%-15%.

Also Read: